| Memo Therapeutics AG

Memo Therapeutics AG announces proof of concept of its huMemoMABTM antibody technology platform



Basel/Zurich, Switzerland, May 23, 2017, Memo Therapeutics AG, a privately-held therapeutic antibody company today announced discovery of its first human antibodies using its proprietary huMemoMABTM antibody discovery platform.

A first series of human monoclonal antibodies against a viral antigen has been identified from a human donor-derived antibody repertoire (antibodyome) library using its huMemoMABTM antibody discovery platform.

Memo Therapeutics AG CSO Christoph Esslinger commented: “This result is a first step towards Memo Therapeutics AG vision to build and exploit cognate human antibodyome libraries from clinically selected donors. We will use this technology for discovery of antibodies with therapeutic potential in a broad range of disease areas.”

“Memo Therapeutics AG has now a best in class antibody discovery platform for discovery from human donors / patients, huMemoMABTM, and immunized rabbits, rbMemoMABTM, respectively. This puts Memo Therapeutics AG in a unique position for any antibody discovery program” CEO Armin Mäder added.

This discovery project has been started through a Swiss Government sponsored CTI program of Memo Therapeutics AG with leading Swiss Universities. It also involves 3 non-interventional clinical study protocols in which more than 70 patients and healthy donors have already been recruited for Memo Therapeutics AG future antibody repertoire library.